@article{3002789,
    title = "Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenström macroglobulinemia: Final analysis of a phase 2 study",
    author = "Kastritis, E. and Gavriatopoulou, M. and Kyrtsonis, M.-C. and Roussou, M. and Hadjiharissi, E. and Symeonidis, A. and Repoussis, P. and Michalis, E. and Delimpasi, S. and Tsatalas, K. and Tsirigotis, P. and Vassou, A. and Vervessou, E. and Katodritou, E. and Gika, D. and Terpos, E. and Dimopoulos, M.A.",
    journal = "Blood advances",
    year = "2015",
    volume = "126",
    number = "11",
    pages = "1392-1394",
    publisher = "American Society of Hematology",
    doi = "10.1182/blood-2015-05-647420",
    keywords = "cyclophosphamide;  dexamethasone;  rituximab;  antineoplastic agent;  cyclophosphamide;  dexamethasone;  rituximab, adult;  aged;  cancer patient;  disease course;  human;  intention to treat analysis;  Letter;  multiple cycle treatment;  phase 2 clinical trial (topic);  priority journal;  progression free survival;  remission;  treatment outcome;  treatment response;  Waldenstroem macroglobulinemia;  clinical trial;  controlled study;  disease free survival;  middle aged;  multicenter study;  phase 2 clinical trial;  randomized controlled trial;  very elderly;  Waldenstrom Macroglobulinemia, Aged;  Aged, 80 and over;  Antineoplastic Combined Chemotherapy Protocols;  Cyclophosphamide;  Dexamethasone;  Disease Progression;  Disease-Free Survival;  Humans;  Middle Aged;  Rituximab;  Treatment Outcome;  Waldenstrom Macroglobulinemia"
}